Pediatric Cancer

FDA to Review Sprycel as Add-On to Chemotherapy in Pediatric Ph+ ALL

By August 30, 2018

The sBLA contains data from the Phase 2 CA180-372 trial evaluating Sprycel as an add-on to chemotherapy regimen modeled on a Berlin-Frankfurt-Munster high-risk backbone in pediatric patients with newly diagnosed Ph+ ALL.

Peripheral Neuropathy Common in Childhood Cancer Survivors

May 15, 2018

Clinical abnormalities consistent with peripheral neuropathy were common and were observed in about half (50.5%) of those treated with neurotoxic chemotherapy

Treatment for Rare Pediatric Cancer Granted Orphan Drug Designation

By May 10, 2018

CLR 131 is an investigational radioiodinated Phospholipid Drug Conjugate (PDC) drug candidate that delivers cytotoxic radiation directly and selectively to malignant cells.

Checklist Developed for Parents of Children With Cancer

April 30, 2018

"Focusing education on the most important topics before the first hospital discharge and only teaching additional topics if parents have time to understand can help parents remember the important, relevant information," the authors said.

FDA Fast Tracks Pedmark for Prevention of Cisplatin-Induced Ototoxicity

By March 21, 2018

The Clinical Oncology Group Protocol ACCL0431 trial enrolled 125 pediatric patients newly diagnosed with a germ cell tumor, hepatoblastoma, medulloblastoma, neuroblastoma, osteosarcoma, or other malignancy.